Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Fyarro (nanoparticle albumin-bound rapamycin)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

EOC Pharma, Kaken Pharma

Drug class:

mTORC1 inhibitor

Related drugs:

No biomarker	Sarcoma	No biomarker	Sarcoma	nanoparticle albumin-bound rapamycin Sensitive: B - Late Trials nanoparticle albumin-bound rapamycin Sensitive : B	nanoparticle albumin-bound rapamycin Sensitive: B - Late Trials nanoparticle albumin-bound rapamycin Sensitive : B
PTEN deletion	Colorectal Cancer	PTEN deletion	Colorectal Cancer	bevacizumab + nanoparticle albumin-bound rapamycin Sensitive: C3 – Early Trials bevacizumab + nanoparticle albumin-bound rapamycin Sensitive : C3	bevacizumab + nanoparticle albumin-bound rapamycin Sensitive: C3 – Early Trials bevacizumab + nanoparticle albumin-bound rapamycin Sensitive : C3
JAK1 S646F	Acute Lymphocytic Leukemia	JAK1 S646F	Acute Lymphocytic Leukemia	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D
IGH-CRLF2 fusion + JAK2 R683G	Acute Lymphocytic Leukemia	IGH-CRLF2 fusion + JAK2 R683G	Acute Lymphocytic Leukemia	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D
STK11 deletion	Non Small Cell Lung Cancer	STK11 deletion	Non Small Cell Lung Cancer	AN2025 + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AN2025 + nanoparticle albumin-bound rapamycin Sensitive : D	AN2025 + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical AN2025 + nanoparticle albumin-bound rapamycin Sensitive : D
SOX9 overexpression	Esophageal Squamous Cell Carcinoma	SOX9 overexpression	Esophageal Squamous Cell Carcinoma	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D
KRAS G12C	Bladder Cancer	KRAS G12C	Bladder Cancer	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D
KRAS G12C	Bladder Cancer	KRAS G12C	Bladder Cancer	sotorasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical sotorasib + nanoparticle albumin-bound rapamycin Sensitive : D	sotorasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical sotorasib + nanoparticle albumin-bound rapamycin Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical sotorasib + nanoparticle albumin-bound rapamycin Sensitive : D	sotorasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical sotorasib + nanoparticle albumin-bound rapamycin Sensitive : D